Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Alcon

- PMLiVE

Xencor’s Novartis-partnered bispecific on hold after patient deaths

The two death’s included one case of CRS

- PMLiVE

CMS proposes coverage scheme for CAR-T therapies

Proposal says it would improve access to CAR-Ts

- PMLiVE

Novartis’ Egatan gains US approval for neglected tropical disease

US approval removes barrier to greater access

- PMLiVE

Novartis first to benefit from NICE advice on ‘patient preference’

Consultancy spin-off looking to expand services

Roche Basel Switzerland

Roche submits Kadcyla for FDA Real-Time review

Aims to extend use in breast cancer patients

AstraZeneca AZ

US, EU regulators back rapid reviews of AZ’s RSV med

Positive top-line data triggered speedy assessments

- PMLiVE

CAR-Ts go head-to-head after NICE clears Kymriah in DLBCL

Novartis agrees pricing deal with NHS England

- PMLiVE

GSK’s Advair Diskus faces first generic in US

Analysts predict around $250m in sales for Wixela Inhub this year

- PMLiVE

Nerve centre gives Novartis edge in clinical trials

Algorithms predict potential delays

- PMLiVE

Novartis aims for 10 blockbuster launches by 2020

Includes new gene therapy Zolgensma

Credit Score

Asking patients to prove they can pay for healthcare is inhumane. Period.

Novartis Gehry Building

Novartis forges AI alliance with Oxford University

Part of Novartis drive to become 'data-driven' pharma company

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links